Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Three new guidelines released for treatment and management of systemic vasculitis

Three new guidelines released for treatment and management of systemic vasculitis

COVID-19 vaccines are effective in 94% of cancer patients, shows study

COVID-19 vaccines are effective in 94% of cancer patients, shows study

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Can convalescent plasma therapy improve COVID-19 outcomes in patients with hematologic cancers?

Baseline use of DMARDs linked with COVID-19 severity in rheumatoid arthritis patients

Baseline use of DMARDs linked with COVID-19 severity in rheumatoid arthritis patients

Study shows CoronaVac to have high seroconversion rate after 40 days

Study shows CoronaVac to have high seroconversion rate after 40 days

Rheumatologists develop a set of consensus statements on COVID-19 vaccination

Rheumatologists develop a set of consensus statements on COVID-19 vaccination

Immune tolerance in hemophilia can be modulated by B cell activating factor

Immune tolerance in hemophilia can be modulated by B cell activating factor

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

Studies suggest mRNA COVID-19 vaccine may have reduced efficacy in patients with blood cancer

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

Freiburg immunologists decipher anti-cancer drug's mode of operation

Freiburg immunologists decipher anti-cancer drug's mode of operation

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

New analysis method could pave the way for important breakthroughs in immunotherapy

New analysis method could pave the way for important breakthroughs in immunotherapy

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Researchers analyze outcomes in patients with primary central nervous system lymphoma

Researchers analyze outcomes in patients with primary central nervous system lymphoma

High-impact clinical trial results could improve kidney-related medical care

High-impact clinical trial results could improve kidney-related medical care

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

Combination of certain drugs can do more harm than good, shows study

Combination of certain drugs can do more harm than good, shows study